[go: up one dir, main page]

WO2012087976A3 - Novel inhibitors of hepatitis c virus replication - Google Patents

Novel inhibitors of hepatitis c virus replication Download PDF

Info

Publication number
WO2012087976A3
WO2012087976A3 PCT/US2011/065925 US2011065925W WO2012087976A3 WO 2012087976 A3 WO2012087976 A3 WO 2012087976A3 US 2011065925 W US2011065925 W US 2011065925W WO 2012087976 A3 WO2012087976 A3 WO 2012087976A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
methods
virus replication
novel inhibitors
subject compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/065925
Other languages
French (fr)
Other versions
WO2012087976A2 (en
Inventor
Brad Buckman
John B. Nicholas
Vladimir Serebryany
Scott D. Seiwert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of WO2012087976A2 publication Critical patent/WO2012087976A2/en
Publication of WO2012087976A3 publication Critical patent/WO2012087976A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The embodiments provide compounds of the general Formulae XV, XVI, XVII and XVIII as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
PCT/US2011/065925 2010-12-21 2011-12-19 Novel inhibitors of hepatitis c virus replication Ceased WO2012087976A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201061425718P 2010-12-21 2010-12-21
US61/425,718 2010-12-21
US201161454438P 2011-03-18 2011-03-18
US61/454,438 2011-03-18

Publications (2)

Publication Number Publication Date
WO2012087976A2 WO2012087976A2 (en) 2012-06-28
WO2012087976A3 true WO2012087976A3 (en) 2012-11-29

Family

ID=46314813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/065925 Ceased WO2012087976A2 (en) 2010-12-21 2011-12-19 Novel inhibitors of hepatitis c virus replication

Country Status (1)

Country Link
WO (1) WO2012087976A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
CN107235965A (en) * 2016-03-29 2017-10-10 上海医药工业研究院 A kind of preparation method of daclatasvir

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX363732B (en) 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Antiviral compounds.
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
DK2368890T3 (en) 2009-06-11 2013-07-22 Abbvie Bahamas Ltd Hepatitis C virus inhibitors
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
TWI548629B (en) * 2010-11-17 2016-09-11 吉李德製藥公司 Antiviral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
PL2635588T3 (en) 2011-11-16 2015-10-30 Gilead Pharmasset Llc Condensed imidazolylimidazoles as antiviral compounds
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
KR20200060782A (en) 2013-01-31 2020-06-01 길리애드 파마셋 엘엘씨 Combination formulation of two antiviral compounds
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
TWI721947B (en) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 Solid forms of an antiviral compound
CN105753944B (en) * 2014-12-19 2019-10-01 正大天晴药业集团股份有限公司 His Wei of Dacca and its derivative prepare intermediate
CN106032388A (en) * 2015-03-11 2016-10-19 浙江九洲药业股份有限公司 A kind of preparation method of daclatasvir compound
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105461701A (en) * 2015-12-14 2016-04-06 上海步越化工科技有限公司 Novel method for synthesizing anti-hepatitis C virus novel medicine daclatasvir
CN105753844A (en) * 2016-02-16 2016-07-13 江苏苏利精细化工股份有限公司 Novel method for synthesizing dimethyl dicarbamate dihydrochloride compound
CN105777719A (en) * 2016-03-29 2016-07-20 安徽联创生物医药股份有限公司 Synthesis method of Daclatasvir
CN107235884B (en) * 2016-03-29 2021-03-26 上海医药工业研究院 Daclatasvir intermediate and preparation method thereof
CN106256825A (en) * 2016-07-04 2016-12-28 四川同晟生物医药有限公司 The synthetic method of his Wei of Dacca
EP3615529B1 (en) 2017-04-26 2024-06-05 Basilea Pharmaceutica International AG, Allschwil Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
CN108640847A (en) * 2018-06-25 2018-10-12 青岛大学 Adjacent aminobenzophenone class compound of the one kind containing fluorene group
KR20220004996A (en) 2019-04-03 2022-01-12 알리고스 테라퓨틱스 인코포레이티드 pyrrole compound
CA3220903A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors
WO2025122482A1 (en) * 2023-12-04 2025-06-12 Henry Ford Health System Methods and compositions to inhibit tribbles 2 for cancer therapy

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021927A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2009102318A1 (en) * 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010065681A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
WO2010099527A1 (en) * 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2010111483A1 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
US20100316607A1 (en) * 2009-06-16 2010-12-16 Yat Sun Or Hepatitis c virus inhibitors
WO2011009084A2 (en) * 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
WO2011031934A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011060000A1 (en) * 2009-11-12 2011-05-19 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2011149856A1 (en) * 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011150243A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021927A2 (en) * 2006-08-11 2008-02-21 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2009102318A1 (en) * 2008-02-12 2009-08-20 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2010065681A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010065668A1 (en) * 2008-12-03 2010-06-10 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
WO2010099527A1 (en) * 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2010111483A1 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
WO2010132601A1 (en) * 2009-05-13 2010-11-18 Gilead Sciences, Inc. Antiviral compounds
US20100316607A1 (en) * 2009-06-16 2010-12-16 Yat Sun Or Hepatitis c virus inhibitors
WO2011009084A2 (en) * 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
WO2011031934A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011060000A1 (en) * 2009-11-12 2011-05-19 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2011149856A1 (en) * 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011150243A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a

Non-Patent Citations (260)

* Cited by examiner, † Cited by third party
Title
DATABASE STN accession no. 007833- 81-9 *
DATABASE STN accession no. 007881- 01-7 *
DATABASE STN accession no. 007881-01-7 *
DATABASE STN accession no. 007882-25-8 *
DATABASE STN accession no. 007882-26-9 *
DATABASE STN accession no. 007882-29-2 *
DATABASE STN accession no. 007882-36-1 *
DATABASE STN accession no. 007882-3-7-2 *
DATABASE STN accession no. 007882-37-2 *
DATABASE STN accession no. 007882-65-6 *
DATABASE STN accession no. 007882-67- 8 *
DATABASE STN accession no. 007882-67-8 *
DATABASE STN accession no. 007882-68-9 *
DATABASE STN accession no. 007882-69-0 *
DATABASE STN accession no. 007883-58-0 *
DATABASE STN accession no. 007883-59-1 *
DATABASE STN accession no. 007883-60-4 *
DATABASE STN accession no. 007883-61-5 *
DATABASE STN accession no. 007883-62-6 *
DATABASE STN accession no. 007883-63-7 *
DATABASE STN accession no. 007883-80-3 *
DATABASE STN accession no. 007883-80-8 *
DATABASE STN accession no. 007883-81-9 *
DATABASE STN accession no. 007883-87-5 *
DATABASE STN accession no. 007883-92- 2 *
DATABASE STN accession no. 007883-92-2 *
DATABASE STN accession no. 007883-93-3 *
DATABASE STN accession no. 007883-94-4 *
DATABASE STN accession no. 007883-95-5 *
DATABASE STN accession no. 007883-96-6 *
DATABASE STN accession no. 007883-97-7 *
DATABASE STN accession no. 007883-98-8 *
DATABASE STN accession no. 007883-99-9 *
DATABASE STN accession no. 007884-00-5 *
DATABASE STN accession no. 007884-01-6 *
DATABASE STN accession no. 007884-01-9 *
DATABASE STN accession no. 007884-02-7 *
DATABASE STN accession no. 007884-03-8 *
DATABASE STN accession no. 007884-06-1 *
DATABASE STN accession no. 007884-07-2 *
DATABASE STN accession no. 007884-07L2 *
DATABASE STN accession no. 007884-09-4 *
DATABASE STN accession no. 007884-13-0 *
DATABASE STN accession no. 007884-14-1 *
DATABASE STN accession no. 007884-85-6 *
DATABASE STN accession no. 007884-89-0 *
DATABASE STN accession no. 009119-84-9 *
DATABASE STN accession no. 087346-53-9 *
DATABASE STN accession no. 087346-55-1 *
DATABASE STN accession no. 087346-56-2 *
DATABASE STN accession no. 087346-57-3 *
DATABASE STN accession no. 087346-58-4 *
DATABASE STN accession no. 087346-59-5 *
DATABASE STN accession no. 087346-60-8 *
DATABASE STN accession no. 087346-61-9 *
DATABASE STN accession no. 087346-62-0 *
DATABASE STN accession no. 087346-65-3 *
DATABASE STN accession no. 087346-70-0 *
DATABASE STN accession no. 087346-72-2 *
DATABASE STN accession no. 087346-73-3 *
DATABASE STN accession no. 087346-75-5 *
DATABASE STN accession no. 087346-76-6 *
DATABASE STN accession no. 087346-81-3 *
DATABASE STN accession no. 087346-84-6 *
DATABASE STN accession no. 087346-91-5 *
DATABASE STN accession no. 22866-17-3 *
DATABASE STN accession no. 228668-67-4 *
DATABASE STN accession no. 228668-68-5 *
DATABASE STN accession no. 228668-73-2 *
DATABASE STN accession no. 228668-74-3 *
DATABASE STN accession no. 228668-75-4 *
DATABASE STN accession no. 228668-76-5 *
DATABASE STN accession no. 228668-77-6 *
DATABASE STN accession no. 228668-78-7 *
DATABASE STN accession no. 228668-79-8 *
DATABASE STN accession no. 228668-80-1 *
DATABASE STN accession no. 228668-81-2 *
DATABASE STN accession no. 228668-82-3 *
DATABASE STN accession no. 228670-54-9 *
DATABASE STN accession no. 228670-61-8 *
DATABASE STN accession no. 228670-62-9 *
DATABASE STN accession no. 228670-63-0 *
DATABASE STN accession no. 228670-64-1 *
DATABASE STN accession no. 228670-65-2 *
DATABASE STN accession no. 228671-24-6 *
DATABASE STN accession no. 228671-70-2 *
DATABASE STN accession no. 228671-74-6 *
DATABASE STN accession no. 228671-79-1 *
DATABASE STN accession no. 228671-81-5 *
DATABASE STN accession no. 228671-92-8 *
DATABASE STN accession no. 228671-93-9 *
DATABASE STN accession no. 228671-99-5 *
DATABASE STN accession no. 228672-00-1 *
DATABASE STN accession no. 228965-93-2 *
DATABASE STN accession no. 228965-95-4 *
DATABASE STN accession no. 228966-02-6 *
DATABASE STN accession no. 228966-03-7 *
DATABASE STN accession no. 228966-04-8 *
DATABASE STN accession no. 228966-06-0 *
DATABASE STN accession no. 228966-07-1 *
DATABASE STN accession no. 228966-08-2 *
DATABASE STN accession no. 228966-09-3 *
DATABASE STN accession no. 228966-10-6 *
DATABASE STN accession no. 228966-17 3 *
DATABASE STN accession no. 228966-18-4 *
DATABASE STN accession no. 228966-19-5 *
DATABASE STN accession no. 228966-71-9 *
DATABASE STN accession no. 228966-73-1 *
DATABASE STN accession no. 228966-88-8 *
DATABASE STN accession no. 228966-89-9 *
DATABASE STN accession no. 228966-90-2 *
DATABASE STN accession no. 228967-06-3 *
DATABASE STN accession no. 228967-07-4 *
DATABASE STN accession no. 228967-08-5 *
DATABASE STN accession no. 228968-76-0 *
DATABASE STN accession no. 228968-76-0. *
DATABASE STN accession no. 239551-98-9 *
DATABASE STN accession no. 23959-40-5 *
DATABASE STN accession no. 239651-88-7 *
DATABASE STN accession no. 239651-89-8 *
DATABASE STN accession no. 239651-90-1 *
DATABASE STN accession no. 239651-91-2 *
DATABASE STN accession no. 239651-92-3 *
DATABASE STN accession no. 239651-93-4 *
DATABASE STN accession no. 239651-96-7 *
DATABASE STN accession no. 239651-97-8 *
DATABASE STN accession no. 239651-99-0 *
DATABASE STN accession no. 239652-00-6 *
DATABASE STN accession no. 239652-02-8 *
DATABASE STN accession no. 239652-03-9 *
DATABASE STN accession no. 239652-04-0 *
DATABASE STN accession no. 239652-05-1 *
DATABASE STN accession no. 239652-06-2 *
DATABASE STN accession no. 239652-07-3 *
DATABASE STN accession no. 239652-08-4 *
DATABASE STN accession no. 239652-O1-7 *
DATABASE STN accession no. 239659-22-3 *
DATABASE STN accession no. 239659-23-4 *
DATABASE STN accession no. 239659-25-6 *
DATABASE STN accession no. 239659-27-8 *
DATABASE STN accession no. 239659-29-0 *
DATABASE STN accession no. 239659-32-5 *
DATABASE STN accession no. 239659-33-6 *
DATABASE STN accession no. 239659-35-8 *
DATABASE STN accession no. 239659-36-9 *
DATABASE STN accession no. 239659-37-0 *
DATABASE STN accession no. 239659-38-1 *
DATABASE STN accession no. 239659-39-2 *
DATABASE STN accession no. 239659-3a-3 *
DATABASE STN accession no. 239659-41-6 *
DATABASE STN accession no. 239659-44-9 *
DATABASE STN accession no. 240883- 60-6 *
DATABASE STN accession no. 240883-53-7 *
DATABASE STN accession no. 240883-55-9 *
DATABASE STN accession no. 240883-56-0 *
DATABASE STN accession no. 240883-5711 *
DATABASE STN accession no. 240883-61-7 *
DATABASE STN accession no. 240883-63-9 *
DATABASE STN accession no. 240883-65-1 *
DATABASE STN accession no. 240883-66-2 *
DATABASE STN accession no. 240883-67-3 *
DATABASE STN accession no. 240883-69- 5 *
DATABASE STN accession no. 240883-71-9 *
DATABASE STN accession no. 240883-73-1 *
DATABASE STN accession no. 240883-75-3 *
DATABASE STN accession no. 240883-76-4 *
DATABASE STN accession no. 240883-77-5 *
DATABASE STN accession no. 240883-79-7 *
DATABASE STN accession no. 240883-81-1 *
DATABASE STN accession no. 240883-83-3 *
DATABASE STN accession no. 240883-85-5 *
DATABASE STN accession no. 240890-46-3 *
DATABASE STN accession no. 240890-48-5 *
DATABASE STN accession no. 240890-50-9 *
DATABASE STN accession no. 240890-51-0 *
DATABASE STN accession no. 240890-53-2 *
DATABASE STN accession no. 240890-54-3 *
DATABASE STN accession no. 240890-56-5 *
DATABASE STN accession no. 240890-58-7 *
DATABASE STN accession no. 240890-60-1 *
DATABASE STN accession no. 240890-61-2 *
DATABASE STN accession no. 240890-64-5 *
DATABASE STN accession no. 240890-65-6 *
DATABASE STN accession no. 240890-67-8 *
DATABASE STN accession no. 240890-68-9 *
DATABASE STN accession no. 240890-71-4 *
DATABASE STN accession no. 240890-72-5 *
DATABASE STN accession no. 240890-74-7 *
DATABASE STN accession no. 240890-75-8 *
DATABASE STN accession no. 240890-77-0 *
DATABASE STN accession no. 240890-78-1 *
DATABASE STN accession no. 242085- 55-7 *
DATABASE STN accession no. 242085-51-3 *
DATABASE STN accession no. 242085-52-4 *
DATABASE STN accession no. 242085-53-5 *
DATABASE STN accession no. 242085-54-6 *
DATABASE STN accession no. 242085-56-8 *
DATABASE STN accession no. 242085-58-0 *
DATABASE STN accession no. 242085-59-1 *
DATABASE STN accession no. 242085-60-4 *
DATABASE STN accession no. 242085-62-6 *
DATABASE STN accession no. 242085-63- 7 *
DATABASE STN accession no. 242085-64-8 *
DATABASE STN accession no. 242085-65-9 *
DATABASE STN accession no. 242085-66-0 *
DATABASE STN accession no. 242085-67-1 *
DATABASE STN accession no. 242085-68-2 *
DATABASE STN accession no. 242085-69-3 *
DATABASE STN accession no. 242085-70-6 *
DATABASE STN accession no. 242088-24-9 *
DATABASE STN accession no. 242088-25-0 *
DATABASE STN accession no. 246469- 50-0 *
DATABASE STN accession no. 246469-42-0 *
DATABASE STN accession no. 246469-43-1 *
DATABASE STN accession no. 246469-47-5 *
DATABASE STN accession no. 246469-49.17 *
DATABASE STN accession no. 246469-51-1 *
DATABASE STN accession no. 246469-52-2 *
DATABASE STN accession no. 246469-56-6 *
DATABASE STN accession no. 246469-57-7 *
DATABASE STN accession no. 246469-59-9 *
DATABASE STN accession no. 246469-60- 2 *
DATABASE STN accession no. 246469-62-4 *
DATABASE STN accession no. 246471-28-2 *
DATABASE STN accession no. 246471-31-7 *
DATABASE STN accession no. 246471-32-8 *
DATABASE STN accession no. 246471-40-8 *
DATABASE STN accession no. 246471-41-9 *
DATABASE STN accession no. 246471-42-0 *
DATABASE STN accession no. 256388-45-0 *
DATABASE STN accession no. 258309-88-4 *
DATABASE STN accession no. 258309-89-5 *
DATABASE STN accession no. 258309-90-8 *
DATABASE STN accession no. 258309-91-9 *
DATABASE STN accession no. 258309-92-0 *
DATABASE STN accession no. 258309-93-1 *
DATABASE STN accession no. 258309-94-2 *
DATABASE STN accession no. 258309-96-4 *
DATABASE STN accession no. 258309-97-5 *
DATABASE STN accession no. 259309-95-3 *
DATABASE STN accession no. 262317-58-7 *
DATABASE STN accession no. 275032-59-1 *
DATABASE STN accession no. 275032-61-5 *
DATABASE STN accession no. 275032-62-6 *
DATABASE STN accession no. 275032-63-7 *
DATABASE STN accession no. 275032-85- 3 *
DATABASE STN accession no. 275032-86-4 *
DATABASE STN accession no. 275032-87-5 *
DATABASE STN accession no. 275032-88-6 *
DATABASE STN accession no. 275033- 55-0 *
DATABASE STN accession no. 275033-67-4 *
DATABASE STN accession no. 275033-69-6 *
DATABASE STN accession no. 307303- 61-2 *
DATABASE STN accession no. 307303-62-3 *
DATABASE STN accession no. 350925-63-3 *
DATABASE STN accession no. 350925-64-2 *
DATABASE STN accession no. 351332-49-4 *
DATABASE STN accession no. 351332-50-7 *
DATABASE STN accession no. 351332-72-3 *
DATABASE STN REGISTRY NUMBERS accession no. 228671-12-2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
CN107235965A (en) * 2016-03-29 2017-10-10 上海医药工业研究院 A kind of preparation method of daclatasvir

Also Published As

Publication number Publication date
WO2012087976A2 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
WO2012087976A3 (en) Novel inhibitors of hepatitis c virus replication
WO2008137779A3 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
WO2009142842A3 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
MX2012003171A (en) Novel macrocyclic inhibitors of hepatitis c virus replication.
WO2009134616A3 (en) Novel inhibitors of hepatitis c virus replication
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
WO2008005511A3 (en) Novel inhibitors of hepatitis c virus replication
WO2007047146A3 (en) Inhibitors of viral replication
IN2012DN02693A (en)
WO2008100867A3 (en) Novel inhibitors hepatitis c virus replication
TW200740851A (en) Novel macrocyclic inhibitors of hepatitis C virus replication
WO2005095403A3 (en) Macrocyclic compounds as inhibitors of viral replication
WO2012083122A8 (en) Inhibitors of influenza viruses replication
WO2013059278A3 (en) Hepatitis c virus inhibitors
TNSN06308A1 (en) Macrocyclic compounds as inhibitors of viral replication
TN2010000468A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
UA95455C2 (en) Macrocyclic inhibitors of hepatitis c virus replication
HK1206273A1 (en) Pharmaceutical composition of a papillomavirus inhibitor
CU20090182A7 (en) NEW MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
CU20090188A7 (en) NEW INHIBITING PEPTIDES OF HEPATITIS C VIRUS REPLICATION
TW200611905A (en) Macrocyclic compounds as inhibitors of viral replication
UA84579C2 (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hepatitis c virus replication
WO2012106722A3 (en) Treatment of bacterial infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11850070

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11850070

Country of ref document: EP

Kind code of ref document: A2